KalVista Pharmaceuticals (KALV) Capital Leases (2017 - 2018)

KalVista Pharmaceuticals (KALV) reported Capital Leases of $58000.0 for Q2 2018, down 50.43% sequentially from $117000.0 in Q1 2018.

KalVista Pharmaceuticals (KALV) Capital Leases (2017 - 2018) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 2 years of Capital Leases data on file, last reported at $58000.0 in Q2 2018.

For the quarter ending Q2 2018, Capital Leases changed N/A year-over-year to $58000.0; the trailing twelve-month figure through Apr 2018 stood at $58000.0 (changed N/A YoY), and the FY2018 full-year result was $58000.0, changed N/A from the prior year.
Capital Leases eased to $58000.0 in Q2 2018, from $117000.0 in the prior quarter.
In the past five years, Capital Leases ranged from a high of $213000.0 in Q3 2017 to a low of $58000.0 in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	KalVista Pharmaceuticals	1.36 Bn	1.36 Bn	49.41 Mn

Download Data